個別化医療バイオマーカーの世界市場

個別化医療バイオマーカーの世界市場は2030年までに437億米ドルに達する見込み

2024年に212億米ドルと推定される個別化医療バイオマーカーの世界市場は、2024年から2030年にかけてCAGR 12.8%で成長し、2030年には437億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである治療選択アプリケーションは、CAGR 15.3％を記録し、分析期間終了までに221億米ドルに達すると予測されます。早期発見／スクリーニング応用分野の成長率は、分析期間中CAGR 10.1％と推定されます。

米国市場は58億米ドルと推定、中国はCAGR17.6％で成長予測

米国の個別化医療バイオマーカー市場は、2024年に58億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに94億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは17.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.1%と11.6%と予測されています。欧州では、ドイツがCAGR 10.2%で成長すると予測されています。

世界の個別化医療バイオマーカー市場- 主要動向と促進要因まとめ

個別化医療バイオマーカーとは何か？

個別化医療バイオマーカーは特定の生物学的指標であり、ヘルスケアプロバイダーが個人の遺伝的体質、疾患プロファイル、その他の個別化された要因に合わせて治療を調整するのに役立ちます。これらのバイオマーカーは通常、特定の病状や治療反応に関連するタンパク質、遺伝子、代謝産物です。個別化医療の文脈では、バイオマーカーは、患者が特定の薬剤や治療にどのように反応するかを予測する上で重要な役割を果たし、臨床医が最も効果的な標的治療を選択し、潜在的な副作用を回避するのに役立ちます。例えば、遺伝子バイオマーカーは、患者が特定の抗がん剤によく反応するかどうか、あるいは特定の遺伝子変異が薬物代謝に影響を及ぼすかどうかを特定するのに役立ちます。

バイオマーカーは、ゲノムシークエンシング、プロテオミクス、メタボロミクスなどの技術によって同定され、その応用範囲は、疾患の早期発見、予後予測、潜在的な薬剤標的の同定から治療効果のモニタリングまで、多岐にわたる。個別化医療バイオマーカーは、腫瘍学、神経学、循環器学、希少疾患など、従来の画一的なアプローチでは最適な治療結果が得られない可能性がある分野で特に重要です。バイオマーカーは、より正確でオーダーメイドの治療を可能にすることで、治療効果を向上させ、患者の転帰を改善します。

なぜ個別化医療バイオマーカー市場は拡大しているのか？

ゲノムおよび分子研究の進歩、慢性疾患の有病率の上昇、精密医療に対する需要の高まりなど、いくつかの重要な要因により、個別化医療バイオマーカー市場は急速に拡大しています。市場成長の主な促進要因の1つは、ゲノムシーケンス技術の利用可能性と応用の拡大です。次世代シーケンサー（NGS）やその他の分子診断技術の進歩により、個人の遺伝子プロファイルを非常に詳細に分析することが可能になりました。これによりヘルスケアプロバイダーは、患者の疾患に影響を与える遺伝的要因をよりよく理解し、特定の治療に対する反応を予測することができます。シーケンシングのコスト低下とデータ解析の改善により、個別化医療バイオマーカーはより身近なものとなり、様々な治療領域における精密医療の採用を促進しています。

個別化医療バイオマーカー市場の成長を促進するもう一つの重要な要因は、がん、糖尿病、心血管疾患、神経疾患などの慢性的で複雑な疾患の有病率の増加です。これらの疾患には複数の遺伝的、環境的、生活習慣的要因が関与していることが多く、従来の方法では治療が困難です。バイオマーカーは、各患者の疾患の特徴を特定するのに役立ち、より効果的な治療につながります。例えば、がんのバイオマーカーは、免疫療法や特定の化学療法剤などの標的療法が有効な患者を特定するのに不可欠です。慢性疾患の世界の負担が増加する中、治療の最適化と患者の転帰の改善には、個別化医療バイオマーカーがますます重要になってきています。

さらに、患者の転帰と費用対効果に重点を置くバリューベースのヘルスケアが重視されるようになり、個別化医療の需要が高まっています。バイオマーカーは、患者固有の生体分子プロファイルに基づき、より効果が期待できる治療法を確実に患者に提供することで、薬剤処方における試行錯誤のアプローチを減らすのに役立ちます。より効率的で成果を重視するヘルスケアへのシフトは、個別化医療バイオマーカー市場をさらに活性化させています。

個別化医療バイオマーカーの将来を形作る主要動向とは？

個別化医療バイオマーカー市場の将来は、バイオマーカー探索における人工知能（AI）と機械学習（ML）の統合の進展、リキッドバイオプシー技術の台頭、マルチオミクスアプローチの重視の高まりなど、いくつかの変革的動向によって形作られています。大きな動向の一つは、バイオマーカーの同定と検証を加速するためのAIとML技術の統合です。機械学習アルゴリズムは、遺伝的、臨床的、人口統計学的情報の膨大なデータセットを解析し、予測バイオマーカーとなり得る、以前は隠されていたパターンや相関関係を発見することができます。バイオマーカー探索におけるAIの活用は、新たな個別化治療の開発に要する時間を大幅に短縮し、診断の精度を向上させ、より適切な治療を可能にする可能性を秘めています。

リキッドバイオプシー技術も、個別化医療バイオマーカーの将来を形作る動向の一つです。従来、組織生検は患者の病気に関する遺伝子情報を収集するために用いられてきたが、血液やその他の体液を分析するリキッドバイオプシーは、侵襲が少なく、より効率的な代替手段として台頭してきています。リキッドバイオプシーは、がん、遺伝子変異、その他の疾患に関連するバイオマーカーを検出することができ、疾患の進行、治療反応、再発をモニターする非侵襲的な方法を提供します。リキッドバイオプシー技術の感度と信頼性が向上するにつれて、診断と治療モニタリングの両面で個別化医療の標準的なツールになると予想されます。

さらに、ゲノミクス、プロテオミクス、メタボロミクス、その他の分野を組み合わせて、個人の生物学的システムを包括的に把握するマルチオミクス・アプローチが重視されるようになってきています。複数のソースからのデータを統合することで、マルチオミクス・アプローチは疾患メカニズムや治療反応についてより深い洞察を提供し、より正確なバイオマーカーの同定を可能にします。患者の生物学に対するこのような総合的な見方は、さらに個別化された正確な医療介入を可能にし、最終的には転帰の改善と副作用の軽減につながります。

個別化医療バイオマーカー市場の成長促進要因は？

個別化医療バイオマーカー市場の成長は、精密医療の進歩、個別化治療に対する需要の増加、慢性疾患の有病率の上昇など、いくつかの重要な要因によってもたらされます。最も重要な促進要因の1つは、患者の個々の遺伝子プロファイルに合わせてヘルスケアの治療を調整することを目的とした精密医療の採用が拡大していることです。ゲノム配列決定とバイオマーカー同定がより洗練されるにつれ、ヘルスケアプロバイダーは転帰を改善し副作用を最小限に抑える、より的を絞った治療を提供できるようになります。バイオマーカーは各患者に最適な治療を特定する上で中心的な役割を果たし、プレシジョン・メディシンに不可欠なものとなっています。

がん、心血管疾患、神経変性疾患などの慢性疾患の罹患率の上昇も、市場の成長を後押ししています。これらの疾患は複雑で多因子にわたることが多く、治療結果を最適化するためには、より個別化された治療アプローチが必要となります。バイオマーカーは、特定の疾患経路を特定し、疾患の進行を予測し、最も効果的な治療法を選択するのに役立ちます。例えば、がんにおけるバイオマーカーは、免疫療法やキナーゼ阻害剤などの標的治療の指針となる特定の変異や分子シグネチャーの同定を可能にします。

治療の有効性と効率性を優先する価値ベースのヘルスケアへの注目の高まりも、個別化医療バイオマーカー市場の主要な促進要因です。ヘルスケア・システムがバリュー・ベース・モデルに移行するにつれて、バイオマーカーに基づいて効果が実証されたオーダーメイド治療を提供する能力が極めて重要になります。個別化医療は、効果のない治療を回避し、試行錯誤のアプローチを最小限に抑えることで、ヘルスケアコストの削減に貢献します。費用対効果が高く、結果を重視するヘルスケアへのシフトは、個別化医療バイオマーカーの採用を加速させ、現代医療の重要な要素となっています。

最後に、新たなバイオマーカー探索技術の研究開発の拡大が市場の成長を後押ししています。マルチオミクス、AI、機械学習の進歩により、新しいバイオマーカーの発見と検証は、より速く、より正確で、より効率的になりつつあります。これにより、個別化医療に新たな扉が開かれ、幅広い疾患に対するより効果的な治療法の開発が可能になりつつあります。技術が向上し、バイオマーカー探索のコストが低下するにつれて、個別化医療バイオマーカー市場は成長し、さまざまな医療分野における精密治療の機会が拡大すると予想されます。

セグメント

アプリケーション（治療選択、早期発見／スクリーニング、診断、モニタリング）、適応症タイプ（腫瘍、神経、糖尿病、自己免疫疾患、循環器、その他の適応症タイプ）

調査対象企業の例

• Abbott Laboratories
• AstraZeneca
• Bio-Rad Laboratories
• Danaher Corporation
• deCODE genetics
• EKF Diagnostics Holdings
• Foundation Medicine
• GE Healthcare
• Guardant Health
• Illumina
• Merck
• Myriad Genetics
• Novartis
• Pfizer
• Qiagen
• Roche
• Signosis
• Singulex
• Tempus AI
• Thermo Fisher Scientific

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Personalized Medicine Biomarkers Market to Reach US$43.7 Billion by 2030

The global market for Personalized Medicine Biomarkers estimated at US$21.2 Billion in the year 2024, is expected to reach US$43.7 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2024-2030. Treatment Selection Application, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$22.1 Billion by the end of the analysis period. Growth in the Early Detection / Screening Application segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 17.6% CAGR

The Personalized Medicine Biomarkers market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.4 Billion by the year 2030 trailing a CAGR of 17.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 11.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.

Global Personalized Medicine Biomarkers Market - Key Trends & Drivers Summarized

What Are Personalized Medicine Biomarkers and How Do They Work?

Personalized medicine biomarkers are specific biological indicators that help healthcare providers tailor medical treatments to an individual’s genetic makeup, disease profile, and other personalized factors. These biomarkers are typically proteins, genes, or metabolites that are associated with specific disease states or therapeutic responses. In the context of personalized medicine, biomarkers play a crucial role in predicting how a patient will respond to a particular drug or treatment, helping clinicians to choose the most effective, targeted therapy and avoid potential side effects. For example, genetic biomarkers can help identify whether a patient will respond well to a particular cancer drug, or whether a specific gene mutation will affect drug metabolism.

Biomarkers are identified through techniques such as genomic sequencing, proteomics, and metabolomics, and their applications are vast, ranging from early disease detection, prognosis prediction, and identifying potential drug targets to monitoring treatment effectiveness. Personalized medicine biomarkers are particularly relevant in fields such as oncology, neurology, cardiology, and rare diseases, where conventional one-size-fits-all approaches may not provide optimal outcomes. By enabling more precise and tailored treatments, biomarkers improve the effectiveness of therapies and enhance patient outcomes.

Why Is the Personalized Medicine Biomarkers Market Expanding?

The personalized medicine biomarkers market is expanding rapidly due to several key factors, including advances in genomic and molecular research, the rising prevalence of chronic diseases, and the growing demand for precision medicine. One of the main drivers of market growth is the increasing availability and application of genomic sequencing technologies. With the advancements in next-generation sequencing (NGS) and other molecular diagnostic technologies, it is now possible to analyze individual genetic profiles in a highly detailed manner. This allows healthcare providers to better understand the genetic factors influencing a patient’s disease and predict how they might respond to specific treatments. The declining costs of sequencing and improvements in data analytics have made personalized medicine biomarkers more accessible, driving the adoption of precision medicine across various therapeutic areas.

Another significant factor driving the growth of the personalized medicine biomarkers market is the increasing prevalence of chronic and complex diseases such as cancer, diabetes, cardiovascular diseases, and neurological disorders. These conditions often involve multiple genetic, environmental, and lifestyle factors, making them difficult to treat with conventional methods. Biomarkers help to identify the unique characteristics of each patient’s disease, leading to more effective treatments. For example, cancer biomarkers are essential in identifying which patients will benefit from targeted therapies, such as immunotherapies or specific chemotherapy agents. As the global burden of chronic diseases rises, personalized medicine biomarkers are becoming increasingly critical for optimizing treatment and improving patient outcomes.

Additionally, the growing emphasis on value-based healthcare, where the focus is on patient outcomes and cost-effectiveness, is driving the demand for personalized medicine. Biomarkers can help reduce the trial-and-error approach in drug prescriptions by ensuring that patients receive therapies that are more likely to work based on their unique biomolecular profile. This shift toward more efficient and outcome-driven healthcare is further fueling the personalized medicine biomarkers market.

What Key Trends Are Shaping the Future of Personalized Medicine Biomarkers?

The future of the personalized medicine biomarkers market is shaped by several transformative trends, including the increasing integration of artificial intelligence (AI) and machine learning (ML) in biomarker discovery, the rise of liquid biopsy technologies, and the growing emphasis on multi-omics approaches. One of the major trends is the integration of AI and ML technologies to accelerate the identification and validation of biomarkers. Machine learning algorithms can analyze vast datasets of genetic, clinical, and demographic information to uncover previously hidden patterns and correlations that could serve as predictive biomarkers. This use of AI in biomarker discovery has the potential to significantly shorten the time required to develop new personalized treatments and improve the accuracy of diagnostics, allowing for better-tailored therapies.

Liquid biopsy technologies are another trend shaping the future of personalized medicine biomarkers. Traditionally, tissue biopsies were used to gather genetic information about a patient’s disease, but liquid biopsies, which analyze blood or other bodily fluids, are emerging as a less invasive, more efficient alternative. Liquid biopsies can detect biomarkers associated with cancer, genetic mutations, and other diseases, offering a non-invasive method to monitor disease progression, treatment responses, and relapse. As liquid biopsy technologies improve in sensitivity and reliability, they are expected to become a standard tool in personalized medicine for both diagnostics and therapeutic monitoring.

Furthermore, there is a growing emphasis on multi-omics approaches, which combine genomics, proteomics, metabolomics, and other disciplines to gather a comprehensive view of an individual’s biological system. By integrating data from multiple sources, multi-omics approaches offer deeper insights into disease mechanisms and treatment responses, enabling more accurate identification of biomarkers. This holistic view of the patient’s biology will allow for even more personalized and precise medical interventions, ultimately leading to better outcomes and reduced side effects.

What Are the Key Drivers of Growth in the Personalized Medicine Biomarkers Market?

The growth of the personalized medicine biomarkers market is driven by several key factors, including advancements in precision medicine, increasing demand for personalized treatments, and the rising prevalence of chronic diseases. One of the most important drivers is the growing adoption of precision medicine, which aims to tailor healthcare treatments to the individual genetic profiles of patients. As genomic sequencing and biomarker identification become more sophisticated, healthcare providers can offer more targeted therapies that improve outcomes and minimize adverse effects. Biomarkers play a central role in identifying the best treatments for each patient, making them indispensable in precision medicine.

The rising incidence of chronic diseases such as cancer, cardiovascular disease, and neurodegenerative disorders is also driving market growth. These conditions are often complex and multifactorial, requiring more personalized treatment approaches to optimize outcomes. Biomarkers help to identify specific disease pathways, predict disease progression, and select the most effective therapies. For instance, biomarkers in cancer allow for the identification of specific mutations or molecular signatures that can guide the use of targeted therapies, such as immunotherapy or kinase inhibitors.

The increased focus on value-based healthcare, which prioritizes the effectiveness and efficiency of treatments, is another key driver of the personalized medicine biomarkers market. As healthcare systems move toward value-based models, the ability to deliver tailored treatments that are proven to work based on biomarkers becomes crucial. Personalized medicine helps to reduce healthcare costs by avoiding ineffective treatments and minimizing trial-and-error approaches. This shift toward cost-effective, outcome-driven healthcare is accelerating the adoption of personalized medicine biomarkers, making them a key component of modern healthcare practices.

Lastly, the expansion of research and development into new biomarker discovery technologies is helping drive the growth of the market. With advancements in multi-omics, AI, and machine learning, the discovery and validation of new biomarkers are becoming faster, more accurate, and more efficient. This is opening new doors for personalized medicine and enabling the development of more effective treatments for a wide range of diseases. As the technology improves and the cost of biomarker discovery decreases, the personalized medicine biomarkers market is expected to grow, offering greater opportunities for precision treatments in various medical fields.

SCOPE OF STUDY:

The report analyzes the Personalized Medicine Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application, Monitoring Application); Indication Type (Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indication Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

• Abbott Laboratories
• AstraZeneca
• Bio-Rad Laboratories
• Danaher Corporation
• deCODE genetics
• EKF Diagnostics Holdings
• Foundation Medicine
• GE Healthcare
• Guardant Health
• Illumina
• Merck
• Myriad Genetics
• Novartis
• Pfizer
• Qiagen
• Roche
• Signosis
• Singulex
• Tempus AI
• Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Personalized Medicine Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Focus on Precision Medicine Throws the Spotlight on Biomarker-Driven Diagnostics
  • Accelerated Demand for Companion Diagnostics Spurs Growth of Personalized Biomarkers
  • Integration of Multi-Omics Data Expands Addressable Market Opportunity for Complex Biomarker Solutions
  • Artificial Intelligence and Machine Learning Propel Growth in Biomarker Discovery and Validation
  • Increasing Oncology Burden Globally Drives Adoption of Tumor-Specific Biomarkers
  • Advancements in Liquid Biopsy Technologies Strengthen Business Case for Non-Invasive Biomarker Testing
  • Growing Role of Pharmacogenomics Generates Demand for Genetic Biomarkers in Personalized Therapies
  • Expansion of Clinical Trials Using Biomarker-Based Stratification Fuels Market Growth
  • Shift Toward Value-Based Healthcare Sustains Growth of Predictive and Prognostic Biomarkers
  • Rising Investment in Precision Oncology Drives Adoption of Tumor Mutation Biomarkers
  • Growing Accessibility to Next-Generation Sequencing Expands Use of Genomic Biomarkers in Routine Care
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Personalized Medicine Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Personalized Medicine Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Personalized Medicine Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Treatment Selection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Treatment Selection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Treatment Selection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Early Detection / Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Early Detection / Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Early Detection / Screening Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Diagnosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Monitoring Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Monitoring Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Monitoring Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Indication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Indication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Indication Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• JAPAN
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• CHINA
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• EUROPE
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Personalized Medicine Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Personalized Medicine Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• FRANCE
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: France 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 71: France Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: France 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• GERMANY
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Germany 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Germany 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Italy 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Italy 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 86: UK Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: UK 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 89: UK Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: UK 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Spain 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 95: Spain Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Spain Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Spain 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Russia 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 101: Russia Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Russia Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Russia 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Rest of Europe Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Rest of Europe 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Personalized Medicine Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 15-Year Perspective for Personalized Medicine Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Asia-Pacific 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Australia 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 122: Australia Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Australia Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Australia 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• INDIA
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 125: India Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: India 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 128: India Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: India Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: India 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: South Korea 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 134: South Korea Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: South Korea Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: South Korea 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Asia-Pacific Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Personalized Medicine Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Latin America 15-Year Perspective for Personalized Medicine Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Latin America 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Latin America 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Argentina 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 155: Argentina Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Argentina Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Argentina 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Brazil 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 161: Brazil Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Brazil Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Brazil 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Mexico 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 167: Mexico Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Mexico Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Mexico 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Latin America Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Latin America 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Personalized Medicine Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Middle East 15-Year Perspective for Personalized Medicine Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Middle East 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Middle East 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Iran 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 188: Iran Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Iran Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Iran 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Israel 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 194: Israel Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Israel Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Israel 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Saudi Arabia Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Saudi Arabia 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: UAE 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 206: UAE Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: UAE Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: UAE 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Middle East Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Rest of Middle East 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030
• AFRICA
  • Personalized Medicine Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Personalized Medicine Biomarkers by Application - Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Africa 15-Year Perspective for Personalized Medicine Biomarkers by Application - Percentage Breakdown of Value Sales for Treatment Selection Application, Early Detection / Screening Application, Diagnosis Application and Monitoring Application for the Years 2015, 2025 & 2030
  • TABLE 218: Africa Recent Past, Current & Future Analysis for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Africa Historic Review for Personalized Medicine Biomarkers by Indication Type - Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Africa 15-Year Perspective for Personalized Medicine Biomarkers by Indication Type - Percentage Breakdown of Value Sales for Other Indication Types, Oncology, Neurology, Diabetes, Autoimmune Diseases and Cardiology for the Years 2015, 2025 & 2030

IV. COMPETITION